摘要
Abstract
Objective To investigate the effects of atherosclerosis-related factors and prognosis of pioglitazone in the treatment of type 2 diabetes patients with coronary heart disease. Methods From August 2010 to January 2012, there were 202 patients in our hospital been treated for treatment of type 2 diabetes with coronary heart disease, and they were randomly divided into the treatment group(101cases) and the control group. The two groups were both given conventional treatment, and on this basis, the treatment group plus pioglitazone treatment(15 mg/d, qd). After 1 year regular follow-up period, compared the atherosclerosis risk factors and adverse cardiovascular events. Results In treatment group, the serum PAI-1 level was 4.15±0.47 ng/ml, P-selectin level was 12.38±3.56 ng/ml, in control group, the serum PAI-1 level was 7.46±1.73 ng/ml, P-selectin level was 15.84±6.32 ng/ml, significant difference(P<0.05);fasting blood glucose, postprandial glucose, fasting insulin, glycated hemoglobin levels and insulin resistance index and acute coronary syndrome, unstable angina pectoris Jinger target vessel revascularization in the treatment group were significantly lower than those in the control group(P<0.05). Conclusion Pioglitazone for the treatment of type 2 diabetes patients with coronary heart disease, which could reduce atherosclerosis risk factors and thus improve prognosis.关键词
吡格列酮/2型糖尿病/冠心病/动脉粥样硬化/相关危险因素Key words
Pioglitazone/Type 2 diabetes/Coronary heart disease/Atherosclerosis/Related risk factors
